Beta Bionics raised a $57 million series C financing round early last year. That financing, which was co-led by a syndicate of venture capital funds with an assist from strategic partner Novo Nordisk, equipped the company to develop iLet, file for FDA clearance and prepare to commercialize the device.
Eighteen months later, Beta Bionics has executed the strategy it outlined at the time of the series C, and persuaded investors to bankroll the next stage of its evolution. New investors Sands Capital and Omega Funds co-led the series D round. British hedge fund Marshall Wace and existing investors such as Soleus Capital, Eventide Asset Management, Farallon Capital and Perceptive Advisors also contributed cash.
